<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical Trial | CSE Tracker</title>
    <link>https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/</link>
      <atom:link href="https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/index.xml" rel="self" type="application/rss+xml" />
    <description>Clinical Trial</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 25 Mar 2021 09:00:00 -0800</lastBuildDate>
    <image>
      <url>https://master--youthful-lamport-190a0e.netlify.app/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>Clinical Trial</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/</link>
    </image>
    
    <item>
      <title>Designing a Randomized Trial with Sample Size Re-estimation - Challenges and Best Practices</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</link>
      <pubDate>Thu, 25 Mar 2021 09:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</guid>
      <description>&lt;p&gt;In this webinar, we will play the part of a sponsor consulting a statistician with the goal of designing a randomized trial with sample-size re-estimation. We will discuss the concept of conditional power and the promising-zone method, and we will present a pragmatic view of some issues, including when to plan the sample-size re-estimation in the course of the accrual, how to select the amount of sample-size increase, and how to operate such trials in practice. We will also discuss the pros- and cons- of using this type of design in relation to the clinical setting in which the trial is designed and endpoints it uses. Moreover, we will discuss the regulators’ views and illustrate our discussion with practical examples.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PSI Journal Club: Survival Analysis</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210324psi-journal-club-survival-analysis/</link>
      <pubDate>Wed, 24 Mar 2021 09:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210324psi-journal-club-survival-analysis/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?&lt;/strong&gt;&lt;br&gt;
&lt;em&gt;Publication: Dominic Magirr, Pharmaceutical Statistics. 2020;1-16&lt;/em&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect&lt;/strong&gt;&lt;br&gt;
&lt;em&gt;Publication: Chang Yu, Xiang Huang, Hui Nian and Philip He, Pharmaceutical Statistics. 2021;1-23&lt;/em&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>The Importance of Representative Samples in Clinical Trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323the-importance-of-representative-samples-in-clinical-trials/</link>
      <pubDate>Tue, 23 Mar 2021 10:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323the-importance-of-representative-samples-in-clinical-trials/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://ds.dfci.harvard.edu/event/data-science-zoominar-the-importance-of-representative-samples-in-clinical-trials/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Event Page&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Cardiac Safety from Preclinical to the Clinic – Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323cardiac-safety-from-preclinical-to-the-clinic-industry-and-regulatory-trends-in-t-qt-and-concentration-qt-studies-for-assessing-qt-prolongation-risks/</link>
      <pubDate>Tue, 23 Mar 2021 08:30:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323cardiac-safety-from-preclinical-to-the-clinic-industry-and-regulatory-trends-in-t-qt-and-concentration-qt-studies-for-assessing-qt-prolongation-risks/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Symposium Agenda (All times are in Pacific Time)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Day 1: March 23, 2021&lt;/strong&gt;&lt;br&gt;
&lt;span style=&#34;color:grey&#34;&gt;
&lt;em&gt;8:30-8:45am:&lt;/em&gt; Introductions&lt;br&gt;
&lt;em&gt;8:45-9:30am:&lt;/em&gt; State-of-the-Art: TQT studies (QT and C-QT Analyses, Challenges &amp;amp; Examples) - Borje Darpo (ERT)&lt;br&gt;
&lt;em&gt;9:30-10:15am:&lt;/em&gt; Cardiac safety and TQT waivers (Types of studies - FIH, Food effect, DDI and timing, Issues with ECG collection) - Jay Mason (Spaulding)&lt;br&gt;
&lt;em&gt;10:15-10:25am:&lt;/em&gt; Sponsor Presentation&lt;br&gt;
&lt;em&gt;10:25-10:40am:&lt;/em&gt; Break&lt;br&gt;
&lt;em&gt;10:40-11:25am:&lt;/em&gt; TBD&lt;br&gt;
&lt;em&gt;11:25am-12:10pm:&lt;/em&gt; New opportunities for C-QT and C-QT in non-ideal scenarios - Lauren Lohmer (Nuventra)&lt;br&gt;
&lt;em&gt;12:10pm-12:40pm:&lt;/em&gt; Panel Discussion&lt;br&gt;
&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Day 2: March 24, 2021&lt;/strong&gt;&lt;br&gt;
&lt;span style=&#34;color:grey&#34;&gt;
&lt;em&gt;8:30-8:45am:&lt;/em&gt; Introductions&lt;br&gt;
&lt;em&gt;8:45-9:30am:&lt;/em&gt; Case Study - Biologics C-QT project supporting a major readout - Yehong Wang (Genentech)&lt;br&gt;
&lt;em&gt;9:30-10:15am:&lt;/em&gt; TBD&lt;br&gt;
&lt;em&gt;10:15-10:25am:&lt;/em&gt; Sponsor Presentation&lt;br&gt;
&lt;em&gt;10:25-10:40am:&lt;/em&gt; Break&lt;br&gt;
&lt;em&gt;10:40-11:25am:&lt;/em&gt; Non-clinical aspects related to the ICH Q&amp;amp;A - Anne Bonneville (Terns Pharmaceuticals)&lt;br&gt;
&lt;em&gt;11:25pm-12:05pm:&lt;/em&gt; Panel Discussion 
&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>COVID-19: Pandemic Preparedness and Lessons Learned</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</link>
      <pubDate>Wed, 10 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;An overview of how COVID-19 progressed&lt;/li&gt;
&lt;li&gt;How can pharmaceutical companies be better prepared? Should there be plans and clinical development strategies in place?&lt;/li&gt;
&lt;li&gt;How do we build resiliency? What steps could/should be implemented at various stages to ‘flatten the curve’?&lt;/li&gt;
&lt;li&gt;Vulnerable communities and minority populations are at a disadvantage. How do we address these health disparities?&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
  </channel>
</rss>
